| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 491.89 | 6.0% |
| Total Income | 507.97 | 5.2% |
| Expenditure | 454.66 | 5.3% |
| PBT | 53.31 | 4.2% |
| Net Profit | 38.67 | 4.4% |
| OPM | 10.97% | 7.08pp |
| NPM | 7.61% | 0.06pp |
| EPS | 2.38 | 4.4% |
FDC Ltd Crosses 22,000 Crore Revenue Mark in FY25, Despite 25.6% Decline in Export Formulation Business
29 May 2025 · 29 May 2025, 11:14 am
Summary
FDC Ltd, a manufacturer and exporter of foods, drugs, and chemicals, reported its financial results for the quarter and year ended March 31, 2025. The company's revenue grew by 8.5% to reach 22,108 crore, despite a 25.6% decline in the export formulation business. The India formulations business contributed 84% of sales and grew by 14.4% YoY, while the API segment grew by 21.1% YoY. The decline in the export formulation business was primarily due to lower sales in the US market and a few ROW markets due to regulatory issues, which have now been addressed.
Key Highlights
- 1
FY25 revenue crossed the 22,000 crore mark
- 2
8.5% growth in Q4FY25
- 3
84% of sales from India formulations business
- 4
14.4% YoY growth in India formulations business
- 5
21.1% YoY growth in API segment
- 6
25.6% decline in export formulation business
- 7
Regulatory issues in US market addressed
- 8
Healthy growth in branded formulations in India market
- 9
15.5% YoY growth in Q4FY25 in Indian Pharmaceutical Market (IPM)
- 10
Electral moved up to 15th rank in IPM in MAT Mar’25
- 11
2nd fastest growing company among Top 25 companies in MAT Mar’25
Management Comments
Company Spokesperson
We’re pleased to share that your Company crossed the 22,000 crore revenue mark in FY25, growing 8.5% to reach 22,108 crore. This milestone reflects the continued strength of our India Formulations business, which contributed 84% of sales and growing with 14.4% YoY, and strong momentum in our API segment, which grew 21.1% YoY. Export Formulation business however reported decline of 25.6% YoY primarily due to lower sales in US market and few of the ROW markets. Lower sales in US market were majorly due to regulatory issues. The regulatory issues of US market have now been addressed, and management believe the business should be back in its normal flow in the coming financial year.
Informational and educational content only. Not investment advice.